Dateline City:
KENILWORTH, N.J.
Additional Analyses from the TECOS Cardiovascular Safety Trial of JANUVIA (sitagliptin) Also to Be Presented
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that researchers will present data from clinical trials
of its investigational diabetes pipeline, JANUVIA
(sitagliptin), and new real-world research in more than 20 scientific
data presentations at the 76th Scientific Sessions of the
American Diabetes Association (ADA) being held in New Orleans, June
10-14, 2016.
Language:
English
Contact:
MerckMedia:Doris Li, 908-246-5701Kristen Drake, 908-236-4223orInvestors:Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more